Below is a structured extraction and summary of the relevant and actionable financial information from Torrent Pharmaceuticals Ltd’s results filing dated 7th November 2025, covering the quarter and half year ended 30 September 2025 (Q2 FY26), with comparisons to prior periods.

1. Auditor’s Note

• Standalone Financial Results Audit Report by B S R & Co. LLP is unqualified with no qualifications, concerns, or issues.
• Consolidated Financial Results Limited Review Report is also unqualified with no material misstatements or qualifications.
• Both reports confirm compliance with applicable accounting standards and SEBI Listing Regulations.
• No changes in accounting policies or material adjustments reported.
• Going concern assumption affirmed by management and auditors.

2. Financial Performance

A. Standalone Financial Results (Rs. in crores)

B. Consolidated Financial Results (Rs. in crores)

3. Detailed Notes / Management Commentary

• Business Performance Highlights:

  • India Market:

    • Revenues Rs. 1,820 crores in Q2 FY26, up 12% YoY.
    • Chronic business grew 13% vs IPM market growth of 11%.
    • Torrent has 21 brands in Top 500 IPM brands; 15 brands > Rs. 100 crores sales.
    • H1 FY26 India revenues Rs. 3,631 crores, up 11%.

  • Brazil:

    • Revenues Rs. 318 crores, up 21% YoY.
    • Constant currency revenues R$ 196 million, up 13%.
    • Torrent grew 15% vs market growth 7%.
    • 65 products under ANVISA review.
    • H1 FY26 revenues Rs. 536 crores, up 17%.

  • United States:

    • Revenues Rs. 337 crores, up 26% YoY.
    • Constant currency revenues $39 million, up 21%.
    • Recent launches achieved target market shares.
    • H1 FY26 revenues Rs. 646 crores, up 23%.

  • Germany:

    • Revenues Rs. 303 crores, up 5% YoY.
    • Constant currency revenues EUR 30 million, down 5%.
    • Growth impacted by supply disruption at third-party supplier.
    • H1 FY26 revenues Rs. 612 crores, up 7%.

• R&D Spend:

  • Rs. 156 crores in Q2 FY26 (5% of revenues), up 8% YoY.
  • Rs. 313 crores in H1 FY26, up 12% YoY.

• Exceptional Items:

  • Rs. 13 crores in Q2 and H1 FY26 relate to regulatory and statutory fees for the proposed acquisition of controlling stake in J.B. Chemicals & Pharmaceuticals Ltd (JB Pharma).

• Taxation:

  • Deferred tax balances remeasured in FY25 due to transition to new tax regime (Section 115BAA) effective FY26, resulting in Rs. 151 crores net reversal of deferred tax liabilities in FY25.

• Acquisition of JB Pharma:

  • Definitive agreement signed on 29 June 2025 to acquire 46.39% stake at Rs. 1,600/share (~Rs. 11,917 crores), plus mandatory open offer at Rs. 1,639.18/share.
  • Additional 2.41% stake may be acquired from employees.
  • Merger planned via scheme of arrangement with share swap ratio of 51 Torrent shares for every 100 JB Pharma shares.
  • Approvals received from Competition Commissions of South Africa and India; SEBI observation received on Draft Letter of Offer.
  • No impact on current quarter or half year results.

• Other Notes:

  • No material changes in accounting policies.
  • No bad debts reported (0.00 ratio).
  • No material impairments or write-downs reported.
  • No restructuring or cost-cutting measures disclosed.

4. Segment Information

• The Group operates in a single business segment: Generic Formulation Business.
• Geographic revenue breakdown (Consolidated Q2 FY26):
  • India: Rs. 1,820 crores (+12% YoY)
  • Brazil: Rs. 318 crores (+21% YoY)
  • USA: Rs. 337 crores (+26% YoY)
  • Germany: Rs. 303 crores (+5% YoY)
• Growth drivers include strong branded business performance and new product launches.

5. Capex, Projects, and Corporate Activity

• Capital Expenditure:

  • Standalone Capex of Rs. 171 crores in H1 FY26 (up from Rs. 126 crores in H1 FY25).
  • Consolidated Capex Rs. 196 crores in H1 FY26 (down from Rs. 226 crores in H1 FY25).

• Corporate Activity:

  • Acquisition of controlling stake in JB Pharma underway (see details above).
  • Exceptional costs of Rs. 13 crores relate to regulatory/statutory fees for this transaction.
  • No other acquisitions, disposals, or restructuring reported.

• Debt and Financing:

  • Standalone and consolidated debt reduced compared to previous year.
  • Debt equity ratio improved:
    • Standalone: 0.24 (Sep 2025) vs 0.34 (Sep 2024)
    • Consolidated: 0.31 (Sep 2025) vs 0.41 (Sep 2024)
  • Interest service coverage ratio improved significantly.
  • Net cash used in financing activities reduced compared to prior year.

6. Standalone vs Consolidated

• Consolidated results include 18 wholly owned subsidiaries.
• Consolidated revenue and profit higher due to international operations.
• Margins higher on standalone basis due to absence of some subsidiary costs.

Additional Key Financial Ratios (Standalone vs Consolidated)

Summary for Investment Analysis Team

• Torrent Pharma delivered strong Q2 FY26 standalone and consolidated financial performance, with revenue growth of 14% (consolidated) and 13.5% (standalone) YoY, and net profit growth of 30% (consolidated) and 30% (standalone) YoY.
• Operating and net profit margins improved, reflecting operational efficiency and strong branded business growth.
• Geographic diversification shows robust growth in India, Brazil, and the US; Germany impacted by supply issues but still positive YoY.
• R&D investment remains healthy at ~5% of revenues, supporting future growth.
• Balance sheet remains strong, with improving debt ratios and healthy liquidity.
• Significant corporate activity underway with the proposed acquisition of JB Pharma (~Rs. 11,917 crores), expected to be transformative; approvals progressing with no impact on current results.
• No auditor qualifications or accounting concerns; financials prepared under Indian GAAP and Ind AS with full compliance.
• No material impairments, restructuring, or bad debts reported.
• Capex increased moderately, supporting capacity and growth.
• Cash flow generation remains robust, with positive operating cash flows and controlled investing and financing outflows.

This comprehensive extraction should assist the investment analysis team in understanding Torrent Pharmaceuticals’ current financial health, growth trajectory, and strategic initiatives.